Background: Only limited data are available regarding the diagnostic accuracy of fecal matrix metalloprotease-9 [MMP-9] for inflammatory bowel disease [IBD]. The aims of our study were to assess the diagnostic accuracy of fecal MMP-9 in patients with active Crohn's disease [CD], ulcerative colitis [UC], and pouchitis, and to compare the diagnostic accuracy of fecal MMP-9 and fecal calprotectin [CP] in IBD. Methods Stool and blood samples were collected in 50 CD, 54 UC, and 34 ileal pouch-anal anastomosis patients before control endoscopies were performed. Biopsies were taken for histologic purposes. The activities of CD, UC, and pouchitis were defined with the use of clinical, endoscopic, and histologic activity scores. Fecal CP and MMP-9 levels were quantified by enzymelinked immunosorbent assay. Results Active CD, UC, and pouchitis were detected in 38%, 54%, and 29% of the patients, respectively. A significant correlation was revealed between fecal CP and the clinical activities of CD and UC, and between fecal CP and the endoscopic activity of UC and pouchitis. Fecal MMP-9 did not correlate with any of the activity indices of CD; however, strong associations were shown between fecal MMP-9 and clinical, endoscopic, and histologic activities of both UC and pouchitis. Conclusions This is the first study assessing the diagnostic accuracy of MMP-9 in different types of IBD. Our results showed that fecal MMP-9 has high sensitivity in the detection of endoscopically active UC and pouchitis. These non-invasive methods help assess intestinal inflammation.
Background
The two main types of inflammatory bowel diseases [IBD]-Crohn's disease [CD] and ulcerative colitis [UC]-are characterized by periods of remission and of relapse. Symptoms, laboratory parameters and the results of endoscopies and other imaging modalities are used in the assessment of disease activity. For monitoring the course and the activity of the disease and the response to different therapies, laboratory and fecal markers proved helpful; however, a biomarker that is absolutely specific to CD or UC has still not been developed. Intestinal inflammation, typical to both diseases, is associated with an acute-phase reaction with the migration of leukocytes to the affected area of the gut. The reason why fecal markers seem to be more specific to assess disease activity than laboratory markers in IBD is the fecal excretion of leukocytes, leukocyte products, and serum proteins. 1 The most commonly used fecal activity marker is calprotectin [CP] . CP, derived predominately from neutrophils, can differentiate between active and inactive IBD and between IBD and irritable bowel syndrome [IBS] . It correlates with the severity of symptoms and may predict relapse-especially in the case of UC. 2, 3 Finally, it can be used as a surrogate marker for the endoscopic response during treatment, given that a normal value of CP is a reliable marker for mucosal healing. 4 Matrix metalloproteases [MMPs] are also released from the neutrophil secretory granules. MMP 1, 2, 3, and 9 have been detected in significantly higher levels in colonic biopsies of UC patients than in controls. 5 MMP-9 has been shown to be significantly increased in the stool of UC patients compared with healthy controls and patients with IBS, and was found to correlate to a high degree with the clinical and endoscopic activity of UC, as well as with fecal CP. 6 A recently published paper on pediatric patients also confirmed the efficacy of fecal MMP-9 in the separation of IBD and non-IBD patients. 7 Since the role of this new fecal activity marker, MMP-9, has previously not been compared in different types of IBD, the aim of our prospective study was to assess the diagnostic accuracy of fecal MMP-9 in patients with active CD, UC, and pouchitis, assessed by clinical, endoscopic, and histologic scores, and to compare the diagnostic accuracy of fecal MMP-9 and fecal CP in IBD. 13 in the case of pouchitis, including the clinical, endoscopic, and histologic assessments of patients with IPAA. The D'Haens score is a widely used scoring system for histologic abnormalities in CD mucosal biopsy specimens that combines active inflammatory changes and chronic architectural changes. 14, 15 Clinically active CD and UC were defined as CDAI > 150 points and pMayo score > 2. Pouchitis was defined as PDAI > 7 points. SES-CD was defined as follows: inactive 0-3; mild 4-10; moderate [11] [12] [13] [14] [15] [16] [17] [18] [19] ; and high ≥ 20. The patients' demographic and clinical data are summarized in Table 1 .
Patients and Methods

Study population
A colonoscopy was performed to evaluate the endoscopic activity in every patient. A day before endoscopy, we requested that patients provide fecal samples. Blood samples were also obtained within 13 days before endoscopy.
Blood inflammatory markers, fecal CP and MMP-9 measurements
Routine laboratory methods were used to determine C-reactive protein, serum iron level, leukocyte number, hematocrit, hemoglobin levels, and the thrombocyte number.
Stool samples were obtained and stored at -20ºC until the determination of fecal CP and MMP-9 levels. For CP measurements, fecal specimens were thawed at 4ºC. CP level was quantified by use of enzyme-linked immunosorbent assay [Quantum Blue, Bühlmann Laboratories, Schönenbuch] according to the manufacturer's 
Colonoscopy, histologic examination
The participants underwent a colonoscopy performed by two experienced endoscopists [TM, ZSZ], either for activity symptoms or simply for a control examination, to evaluate the macroscopic inflammation of the colon or the pouch. Biopsies were taken for histology during the endoscopy. Histologic variables were scored by a single pathologist [LT]. 
Statistical analyses
Ethical considerations
The study protocol was approved by the Ethical Committee of the University of Szeged. All subjects provided written and informed consent to participation. 
Results
Endoscopic and disease activity
Fecal CP and MMP-9 levels in CD patients
Median fecal CP was 500 µg/g and MMP-9 was 1.53 ng/mL in endoscopically active and 142 µg/g and 0.61 ng/mL in endoscopically inactive patients, respectively. Median fecal CP concentrations were 650 and 159 µg/g in patients with clinically active and inactive disease, 
Fecal CP and MMP-9 levels in UC patients
Median fecal CP was 300 µg/g and MMP-9 was 6.17 ng/mL in endoscopically active patients and 121 µg/g and 0. Graphs by Chron disease Graphs by Chron disease
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Inactive Active Figure 1 . Box-and-whisker plots for comparison of faecal CP and MMP-9 medians between endoscopically active and non-active CD be determined. The best cut-off of MMP-9 for the separation of clinically active and inactive UC patients was 0.35 ng/mL, with a sensitivity of 93% and a specificity of 63% [AUC = 0.74]. In the case of endoscopic activity, the optimal cut-off value proved to be 0.20 ng/ mL, with a sensitivity of 96% and a specificity of 75% [AUC = 0.806] [ Figure 2 ]. Significant correlation was shown between fecal CP and MMP-9 levels [r = 0.73, p < 0.001]. Box-and-whisker plots for comparisons of fecal CP and MMP-9 medians between endoscopically active and non-active UC are shown in Figure 3 .
Fecal CP and MMP-9 levels in patients with and without pouchitis
The median fecal CP concentration was 560 µg/g in patients with pouchitis and 96. Figure 4 ]. Significant correlation was shown between fecal CP and MMP-9 levels [r = 0.55, p = 0.009]. Box-and-whisker plots for comparisons of fecal CP and MMP-9 medians between endoscopically active and non-active IPAA patients are shown in Figure 5 . Correlation of fecal CP and MMP-9 with the clinical, endoscopic, and histologic activities in CD, UC, and pouchitis are summarized in Table 2 . 
Discussion
This prospective study revealed significant correlation between fecal CP and the endoscopic activity of both UC and pouchitis. Strong association was revealed between fecal MMP-9 and clinical, endoscopic, and histologic activities of both UC and pouchitis. The assessment of mucosal inflammation is known to be crucial in optimizing therapy in patients with IBD. Therefore, non-invasive markers, substituting for endoscopy, play a very important role in the follow-up of the patients. CP is a widely studied fecal activity marker in IBD. It proved to be effective for measuring intestinal inflammation, since the fecal concentration of CP is elevated both in CD and UC. 1617 , 18 It appears to better reflect disease activity in UC than in CD, but fecal CP has not been found to be useful in distinguishing UC from CD. 19, 20 Very few data are available regarding the role of fecal MMP-9 in diagnosing and predicting disease activity in IBD. MMPs partake in normal mucosal defence, as well as playing a role both in the evolution of the inflammatory processes and in the pathogenesis of inflammatory diseases. 21 The study of Mäkitalo et al. revealed that serum levels of MMP-7, 8, and 9 are elevated in active IBD. In this study, MMP-7 was the most prominent marker that indicated a response to steroid therapy. 22 Although the authors could not demonstrate alterations in MMP-9 levels following the therapy, serum MMP-9 levels were elevated at baseline in patients with active IBD. There results did not support a role for serum MMP-9 as a marker for disease activity; however, a previous study confirmed an increased expression of MMP-9 in the mucosa of IBD patients. 23 We previously confirmed that fecal MMP-9 is a reliable marker in separating UC and non-IBD patients, the higher levels being associated with more active disease. 6 The first study on fecal MMP-9 in pediatric patients revealed that MMP-9 levels were significantly lower in CD than in UC, whereas fecal CP was not useful in differentiating pediatric UC and CD. 7 Our study aimed to examine fecal MMP-9, a very new fecal activity marker for such indication, and whether the diagnostic accuracy of fecal MMP-9 is comparable with fecal CP. The patient samples included some taken from patients on maintenance treatment, who were referred for a colonoscopy. As our results showed, fecal CP was not useful in differentiating patients with CD and UC, as the values were comparable, confirming the above mentioned data. However, fecal MMP-9 showed a stronger association with UC than with CD, and also correlated solely with the clinical symptoms of pouchitis in our cohort. It is also important to note that fecal MMP-9 correlated not only with clinical activities of UC and pouchitis, but also with endoscopic and histologic activities, and thus can be useful for assessing mucosal inflammation during the follow-up period.
Whereas the diagnostic role of fecal CP in pouchitis has previously been examined in some studies, limited data are available on the role of MMP-9 in pouchitis. In the case of pediatric-onset UC patients, most pouch samples showed an increased expression of MMP-3 and MMP-7 in pouchitis. 24 MMP-1 and MMP-2 concentrations in the mucosal biopsies were increased in pouchitis compared with uninflamed pouches of patients with UC, in the study of Stallmach et al. 25 Ulisse et al. revealed strong MMP-9 and MMP-2 activities in the inflamed pouch, reduced after antibiotic treatment. 26 Our results revealed that none of the routinely used laboratory activity markers correlates significantly with fecal CP and MMP-9 levels in CD or UC. In pouchitis, fecal markers correlated only with thrombocytosis. Thrombocytosis is a common finding in IBD, suggestive of active disease. Correlation between thrombocytosis and elevated fecal markers can be explained by the fact that both are potential markers of clinical disease activity. The level of fecal CP significantly increased in clinically active colonic CD and UC, although fecal MMP-9 showed a significantly stronger correlation with the activity of UC than with that of CP, and this was the only marker correlating with the clinical symptoms of pouchitis. Significant correlation was also shown between fecal CP and MMP-9 levels in patients with UC and pouchitis.
The authors are aware of the limitations of the study. The main limiting factor of the study is the relatively low number of enroled patients with regard to the different types of the studied disease; however, the accurately performed diagnostic and scoring procedures and statistical analyses are strengths of this study.
Conclusion
This is the first study assessing the diagnostic accuracy of fecal MMP-9 in the different types of IBD. Our results showed that fecal MMP-9 has high sensitivity in the detection of endoscopically active UC and pouchitis, and these non-invasive methods help in assessing intestinal inflammation. 
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